Please turn JavaScript on

BIOENGINEER.ORG

Subscribe to BIOENGINEER.ORG’s news feed.

Click on “Follow” and decide if you want to get news from BIOENGINEER.ORG via RSS, as email newsletter, via mobile or on your personal news page.

Subscription to BIOENGINEER.ORG comes without risk as you can unsubscribe instantly at any time.

You can also filter the feed to your needs via topics and keywords so that you only receive the news from BIOENGINEER.ORG which you are really interested in. Click on the blue “Filter” button below to get started.

Website title: BIOENGINEER.ORG - Bioengineering

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  43.34 / day

Message History

In an impressive leap forward in cancer immunology, a recent study has shed new light on the intricate molecular interplay that fosters tumor immune evasion. The research, conducted by Lee et al. and published in Experimental & Molecular Medicine in June 2026, reveals how the phospholipase D enzymes, PLD1 and PLD2, orchestrate an immunosuppressive tumor […]

Read full story
In an era where sustainability and resource efficiency have become imperative in architecture and construction, a pioneering study by Aalto University architect and researcher Jaakko Torvinen breathes new life into the overlooked potential of what is known as “misfit wood.” This research challenges long-standing norms in timber utilization by focusing on the structural viability...

Read full story
In a groundbreaking development in nephrology, the Phase III FIND-CKD trial has delivered compelling evidence that finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, significantly decelerates kidney function decline in adults afflicted with chronic kidney disease (CKD) without diabetes. This pivotal trial, heralded as the largest of its kind, casts new ligh...

Read full story
Emerging Concerns Over a Common Blood Pressure Medication and Kidney Health in Type 2 Diabetes Patients A groundbreaking study unveiled at the 63rd European Renal Association (ERA) Congress in Glasgow has brought to light unsettling evidence regarding the safety of a widely prescribed class of antihypertensive drugs in people with type 2 diabetes (T2D). The […]

Read full story
In a landmark achievement for vaccine science, researchers at the University of Cambridge and their spin-out company DIOSynVax have successfully completed the first human clinical trial of a universal vaccine targeting Sarbeco coronaviruses, the broad group that includes SARS-CoV-2 and related bat viruses with pandemic potential. This pioneering trial demonstrates the vaccine’s ...

Read full story